Is Abbott Wavering On Alere Acquisition Plans?
This article was originally published in The Gray Sheet
Comments by Abbott officials during a recent earnings call have fueled questions about whether the firm remains committed to going through with its $5.8 billion purchase of point-of-care diagnostics company Alere, which is under federal investigation for sales practices.
You may also be interested in...
Siemens Healthineers' product mix of diagnostics and imaging products meant it was in the middle of a very dynamic situation when COVID-19 struck.
The WHO’s new "living guideline" against remdesivir’s use in hospitalized patients notwithstanding, some key opinion leaders in India see a role for the antiviral, but underscore that COVID-19 is still in its infancy and all repurposed therapies for the disease still have a long way to go. They also see the US remdesivir studies as more robust.
Join us for a brief audio tour around the past week's major global biopharma industry developments, in this podcast version of Scrip's Five Must-Know Things.